316 related articles for article (PubMed ID: 18226859)
1. Targeted therapy for uveal melanoma.
Triozzi PL; Eng C; Singh AD
Cancer Treat Rev; 2008 May; 34(3):247-58. PubMed ID: 18226859
[TBL] [Abstract][Full Text] [Related]
2. Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells.
Ye M; Hu D; Tu L; Zhou X; Lu F; Wen B; Wu W; Lin Y; Zhou Z; Qu J
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):497-504. PubMed ID: 18234991
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic implications of the emerging molecular biology of uveal melanoma.
Patel M; Smyth E; Chapman PB; Wolchok JD; Schwartz GK; Abramson DH; Carvajal RD
Clin Cancer Res; 2011 Apr; 17(8):2087-100. PubMed ID: 21444680
[TBL] [Abstract][Full Text] [Related]
4. Uveal melanoma and macular degeneration: molecular biology and potential therapeutic applications.
Economou MA
Acta Ophthalmol; 2008 Dec; 86(8):930-1. PubMed ID: 19086934
[TBL] [Abstract][Full Text] [Related]
5. The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells.
Girnita A; All-Ericsson C; Economou MA; Aström K; Axelson M; Seregard S; Larsson O; Girnita L
Acta Ophthalmol; 2008 Nov; 86 Thesis 4():26-34. PubMed ID: 19032679
[TBL] [Abstract][Full Text] [Related]
6. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.
Eberle J; Kurbanov BM; Hossini AM; Trefzer U; Fecker LF
Drug Resist Updat; 2007 Dec; 10(6):218-34. PubMed ID: 18054518
[TBL] [Abstract][Full Text] [Related]
7. Molecularly targeted therapy for melanoma: current reality and future options.
Becker JC; Kirkwood JM; Agarwala SS; Dummer R; Schrama D; Hauschild A
Cancer; 2006 Nov; 107(10):2317-27. PubMed ID: 17039502
[TBL] [Abstract][Full Text] [Related]
8. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.
Tran MA; Smith CD; Kester M; Robertson GP
Clin Cancer Res; 2008 Jun; 14(11):3571-81. PubMed ID: 18519791
[TBL] [Abstract][Full Text] [Related]
9. Role of the extracellular matrix proteins in the resistance of SP6.5 uveal melanoma cells toward cisplatin.
Bérubé M; Talbot M; Collin C; Paquet-Bouchard C; Germain L; Guérin SL; Petitclerc E
Int J Oncol; 2005 Feb; 26(2):405-13. PubMed ID: 15645125
[TBL] [Abstract][Full Text] [Related]
10. Molecular targets in melanoma from angiogenesis to apoptosis.
Sosman JA; Puzanov I
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2376s-2383s. PubMed ID: 16609062
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate.
Hofmann UB; Kauczok-Vetter CS; Houben R; Becker JC
Clin Cancer Res; 2009 Jan; 15(1):324-9. PubMed ID: 19118061
[TBL] [Abstract][Full Text] [Related]
12. New therapeutic agents in uveal melanoma.
Velho TR; Kapiteijn E; Jager MJ
Anticancer Res; 2012 Jul; 32(7):2591-8. PubMed ID: 22753717
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis and melanoma: how new insights are effecting the development of new therapies for melanoma.
Hersey P
Curr Opin Oncol; 2006 Mar; 18(2):189-96. PubMed ID: 16462190
[TBL] [Abstract][Full Text] [Related]
14. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways.
Wallerand H; Reiter RR; Ravaud A
Curr Opin Urol; 2008 Sep; 18(5):524-32. PubMed ID: 18670279
[TBL] [Abstract][Full Text] [Related]
15. Prospects for non-immunological molecular therapeutics in melanoma.
Eustace AJ; Mahgoub T; Tryfonopoulos D; O'Donovan N; Crown J
J BUON; 2010; 15(1):9-18. PubMed ID: 20414921
[TBL] [Abstract][Full Text] [Related]
16. Uveal melanoma: natural history and treatment options for metastatic disease.
Wöll E; Bedikian A; Legha SS
Melanoma Res; 1999 Dec; 9(6):575-81. PubMed ID: 10661768
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen inhibits tumor cell invasion and metastasis in mouse melanoma through suppression of PKC/MEK/ERK and PKC/PI3K/Akt pathways.
Matsuoka H; Tsubaki M; Yamazoe Y; Ogaki M; Satou T; Itoh T; Kusunoki T; Nishida S
Exp Cell Res; 2009 Jul; 315(12):2022-32. PubMed ID: 19393235
[TBL] [Abstract][Full Text] [Related]
18. [Kinase inhibitors for the therapy of malignant melanoma].
Becker JC; Schrama D; Bröcker EB; Houben R
J Dtsch Dermatol Ges; 2005 Oct; 3(10):762-7. PubMed ID: 16194153
[TBL] [Abstract][Full Text] [Related]
19. GPNMB expression in uveal melanoma: a potential for targeted therapy.
Williams MD; Esmaeli B; Soheili A; Simantov R; Gombos DS; Bedikian AY; Hwu P
Melanoma Res; 2010 Jun; 20(3):184-90. PubMed ID: 20375921
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met.
Yan D; Zhou X; Chen X; Hu DN; Dong XD; Wang J; Lu F; Tu L; Qu J
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1559-65. PubMed ID: 19029026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
